Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
12 Cards in this Set
- Front
- Back
|
PDE-5 inhibitors
|
Sildenafil(viagra), Tadalafil(cialis), Varedenafil(levitra)
|
|
|
Intra-urethral alprostadil are given in what form?
|
As a suppository
|
|
|
Why should the initial dose of intra-urethral alprostadil be administered under healthcare supervision?
|
risk of syncope
|
|
|
Intracavernous vasoactive drug injection should initially be administered under healthcare supervision (T/F)
|
True
|
|
|
What is the MOA of PDE-5 inhibitors?
|
Inhibits PDE-5 enzyme in smooth muscle resulting in relaxation & vasodilation
|
|
|
What ADE do all of the PDE-5 inhibitors have?
|
Peripheral vasodilation—flushing, h/a, nasal congestion, dyspepsia
|
|
|
Which PDE-5 inhibitors cause visual disturbances?
|
Sildenafil (Viagra) and Varedenafil (levitra)
|
|
|
Which PDE-5 inhibitor causes QT prolongation?
|
Varendenafil (levitra)
|
|
|
What drug interactions do PDE-5 inhibitors have?
|
Nitrates can cause hypotensive effects so PDE-5's are contraindicated with nitrate use
|
|
|
Intra-urethral alprostadil MOA
|
Relaxes smooth muscle of cavernosal arteries
|
|
|
Intra-urethral alprostadil ADEs
|
Hypotension, arrhythmias, pain
|
|
|
Intra-urethral alprostadil drug interactions
|
Heparin (increased risk of bleeding)
|
